Cargando…

Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma

OBJECTIVE: To study the expression of Neighbor of Brca1 gene (NBR1) in clear cell renal cell carcinoma (ccRCC), renal cancer cells and the chemoresistance cells and to elucidate its clinical prognostic and chemoresistance value. MATERIALS AND METHODS: We screened the NBR1 mRNA in ccRCC from The Canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Wen, Xiong, Zhiyong, Yuan, Changfei, Bao, Lin, Liu, Di, Yang, Xiong, Li, Wencheng, Tong, Junwei, Qu, Yan, Liu, Lei, Xiao, Haibing, Yang, Hongmei, Zhang, Xiaoping, Chen, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706915/ https://www.ncbi.nlm.nih.gov/pubmed/29212269 http://dx.doi.org/10.18632/oncotarget.21999

Ejemplares similares

Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress
por: Xiong, Zhiyong, et al.
Publicado: (2020)

Downregulation of ubiquitin-specific protease 2 possesses prognostic and diagnostic value and promotes the clear cell renal cell carcinoma progression
por: Meng, Xiangui, et al.
Publicado: (2020)

Long non-coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma
por: Xiao, Haibing, et al.
Publicado: (2017)

Low Expression Levels of SLC22A12 Indicates a Poor Prognosis and Progresses Clear Cell Renal Cell Carcinoma
por: Xu, Jiaju, et al.
Publicado: (2021)

Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma
por: Liu, Yuenan, et al.
Publicado: (2020)

Overexpression of PPT2 Represses the Clear Cell Renal Cell Carcinoma Progression by Reducing Epithelial-to-mesenchymal Transition
por: Yuan, ChangFei, et al.
Publicado: (2020)

HIF2α promotes tumour growth in clear cell renal cell carcinoma by increasing the expression of NUDT1 to reduce oxidative stress
por: Shi, Jian, et al.
Publicado: (2021)

Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma
por: Cao, Qi, et al.
Publicado: (2018)

Tumor Cell “Slimming” Regulates Tumor Progression through PLCL1/UCP1‐Mediated Lipid Browning
por: Xiong, Zhiyong, et al.
Publicado: (2019)

Tumor Cell “Slimming” Regulates Tumor Progression through PLCL1/UCP1‐Mediated Lipid Browning
por: Xiong, Zhiyong, et al.
Publicado: (2022)

LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation
por: Cheng, Gong, et al.
Publicado: (2020)

As a prognostic biomarker of clear cell renal cell carcinoma RUFY4 predicts immunotherapy responsiveness in a PDL1-related manner
por: Miao, Daojia, et al.
Publicado: (2022)

NNT‐induced tumor cell “slimming” reverses the pro‐carcinogenesis effect of HIF2a in tumors
por: Xiong, Zhiyong, et al.
Publicado: (2021)

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma
por: Song, Zhengshuai, et al.
Publicado: (2020)

CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/β-catenin signaling pathway
por: Wang, Qi, et al.
Publicado: (2021)

Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis
por: Feng, Chunxiang, et al.
Publicado: (2020)

Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma
por: Tan, Diaoyi, et al.
Publicado: (2023)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

A Novel Ferroptosis-Related Pathway for Regulating Immune Checkpoints in Clear Cell Renal Cell Carcinoma
por: Gao, Su, et al.
Publicado: (2021)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer
por: Alifrangis, C, et al.
Publicado: (2016)

METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma
por: Xu, Tianbo, et al.
Publicado: (2021)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Wei, Yuang, et al.
Publicado: (2021)

Downregulation of miR-29c promotes muscle wasting by modulating the activity of leukemia inhibitory factor in lung cancer cachexia
por: Xie, Kairu, et al.
Publicado: (2021)

Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma
por: Yuan, Huiyang, et al.
Publicado: (2023)

ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma
por: Xu, Tianbo, et al.
Publicado: (2020)

Impact of inflammation and immunotherapy in renal cell carcinoma
por: Shi, Jian, et al.
Publicado: (2020)

The Identification of Critical m(6)A RNA Methylation Regulators as Malignant Prognosis Factors in Prostate Adenocarcinoma
por: Xu, Jiaju, et al.
Publicado: (2020)

High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma
por: Wang, Xuegang, et al.
Publicado: (2023)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

ENO2 as a Biomarker Regulating Energy Metabolism to Promote Tumor Progression in Clear Cell Renal Cell Carcinoma
por: Shi, Jian, et al.
Publicado: (2023)

Extracellular vesicles-released parathyroid hormone-related protein from Lewis lung carcinoma induces lipolysis and adipose tissue browning in cancer cachexia
por: Hu, Wenjun, et al.
Publicado: (2021)

Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma
por: Xi, Wei, et al.
Publicado: (2016)

Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma
por: Xiao, Wen, et al.
Publicado: (2021)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
por: Wu, Zeshen, et al.
Publicado: (2022)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_m3valroodtfi4h3uafrda5tjc5